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The correct execution of morphogenetic patterns and the
homeostatic control of tissue integrity require that cell
proliferation be tightly balanced against cell differentiation
and death. Among cell-intrinsic mechanisms deputed to
restraining cell proliferation, negative feedback loops have a
prominent role, given their ability to operate on sensing the
generation and/or accumulation of intracellular signals.
MIG6/RALT (encoded by the ERRFI1 gene) is a cytosolic
adaptor/scaffold protein (Figure 1a). ERRFI1 transcription is
induced by as diverse stimuli as growth factors, hormones,
vitamins, hypoxia, mechanical and metabolic stress,1 a notion
that would predicate MIG6 involvement in a wide range of
physiological and physiopathological scenarios. Yet, research
on MIG6 has focused primarily on its function in growth
control, namely on its capacity of acting as a feedback inhibitor
of ErbB and, possibly, MET receptor tyrosine kinases
(RTKs),2,3 with EGFR being the most investigated receptor
model. EGFR activation increases ERRFI1 transcription in a
RAS-ERK-dependent fashion, leading to accumulation of the
MIG6 protein within 60–90 min.4 In turn, MIG6 binds to the
tyrosine kinase domain of the ligand-occupied EGFRs,
causing their catalytic inactivation5,6 and endocytosis-depen-
dent degradation7 (Figure 1). This two-tiered mechanism of
receptor inhibition is thought to provide for strong and durable
attenuation of EGFR mitogenic signaling. Consistently,
Errfi1 / mice show a fully penetrant skin phenotype, that
is, epidermal hyperplasia and markedly increased suscept-
ibility to skin carcinogenesis, which was formally proved to be
caused by excess Egfr signaling.8 Hence, Mig6 is an essential
negative feedback regulator of Egfr in mouse epidermis.
Germline disruption of Errfi1 in mice also causes variably
penetrant phenotypes characterized by hyperplastic lesions,
which may progress to frank malignancy, in the endometrium
and epithelia lining the gastrointestinal tract, biliary ducts,
gallbladder, bronchial airways and mammary gland.
In addition, Errfi1 null mice suffer from an early-onset
degenerative joint disease, caused by aberrant proliferation
of precursor mesenchymal cells in cartilages.8–12 An unan-
swered question is whether these phenotypes are reflective of
excess cell proliferation driven by unopposed ErbB or MET
signaling. A related issue is whether it is satisfactory to
rationalize the biological finalism of MIG6 induction by a
plethora of stimuli solely in the context of MIG6-driven RTK
inhibition. A few recent publications provide insightful
advances concerning the above issues.
Hopkins et al.9 set out to study mammary gland develop-
ment in Errfi1 null mice. They observed an altered pattern of
morphogenesis characterized by decreased ductal branching
and widespread luminal filling of terminal end buds (TEBs).
Concentrating on TEBs, they discovered that supernumerary
luminal cells accumulated as a consequence of reduced
apoptotic cell death. This phenotype was not determined by
excess ErbB signaling, but turned out to be caused by
defective Abl activity. In detail, Mig6 was found to bind and
activate the Abl tyrosine kinase domain. This event, possibly
in conjunction with enhanced nuclear localization of Abl,
ignited a p73-dependent pro-apoptotic pathway.9 Of note,
Hopkins et al.9 found that Mig6 became competent to activate
Abl only in absence of signals generated by active ErbB RTKs
via Src family kinases (Figure 1b), which led to the proposal
that Mig6 may regulate ErbB or Abl kinase activity in a
mutually exclusive fashion. In this model, TEB luminal cells
that are pushed away from the basal membrane on epithelial
multilayering end up receiving an insufficient ErbB-Src signal,
which sets Mig6 free to activate Abl and launch an apoptotic
program.
The Hopkins et al.9 paper provided the first mechanistically
defined evidence that MIG6 may exert a pro-apoptotic
function. Excitingly enough, a coeval study by Chen et al.13
reported that in Errfi1 /þ mice the rate of apoptosis of
pancreatic b-cells experiencing endoplasmic reticulum (ER)
stress (that is, under experimental conditions that mimic type
2 diabetes) is lower than in control littermates. Complemen-
tary experiments in cultured cells showed that MIG6 over-
expression increased the rate of apoptotic cell death, whereas
reducing MIG6 protein abundance by RNAi had the opposite
effect. Importantly, induction of ER stress in cultured cells
caused accumulation of ERRFI1 mRNA.13 Although Chen
et al.13 did not provide molecular details on how MIG6
favors apoptosis in ER-stressed b-cells, it is tantalizing that
previous work had proposed a role for ABL in the induction of
apoptosis in cells experiencing ER stress.14 Hence, it will be
important to test whether MIG6 may instigate apoptosis in all
stressing conditions characterized by increased MIG6
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expression1 and, if so, whether ABL is an obligatory MIG6
pro-apoptotic partner. The obvious lingering question is does
MIG6 have a pro-apoptotic role also in the course of tumor
pathogenesis? A convincing affirmative answer comes from a
recent paper that showed ablation of Errfi1 accelerated
the development of endometrial carcinoma in a Pten
null context by suppressing apoptosis via still undefined
mechanism/s.15
MIG6 biology was further enriched by a recent paper that
provides initial evidence that MIG6 can regulate cellular
senescence.16 Xie et al.16 showed that MIG6 is highly
expressed in human embryonic diploid fibroblasts under-
going either replicative or oncogene-induced senescence.
Overexpression of wtMIG6, but not a MIG6 mutant
unable to bind to EGFR, was sufficient to enhance
replicative senescence, a phenotype observed also on
pharmacological suppression of EGFR. Conversely, redu-
cing MIG6 expression limited RASV12-induced senes-
cence. This analysis provides prima facie evidence that
EGFR inhibition by MIG6 contributes to cellular senes-
cence (Figure 1) and is in keeping with a report that
pharmacological suppression of EGFR drives senescence
of epithelial cervical cells infected with HPV-16.17 At
variance with growing cells, accumulation of ERRFI1
mRNA in senescent fibroblasts was independent of RAS-
ERK signaling and instead required recruitment of
FOXO3A, an ascertained driver of cell senescence,18 onto
the ERRFI1 promoter.16 Thus, MIG6 joins the company of
feedback inhibitors (some of which are themselves FOXO
targets) whose expression is induced and maintained in
Figure 1 (a) Schematic outline of MIG6 structural features. The endocytic domain (ED) couples MIG6 to endocytic proteins, thus instructing the endocytosis-dependent
degradation of MIG6-bound EGFR; the ErbB-binding region (EBR) consists of the AH1 (green) and AH2 (violet) subdomains and directs MIG6 binding to the EGFR (catalytic
inhibition) and ABL (catalytic activation) tyrosine kinase (TK) domains. (b) Regulation of EGFR and ABL kinase activity by MIG6. Top: ligand-induced dimerization of EGFR
leads to the formation of asymmetric kinase dimers in which the C-lobe of a donor kinase (gray) contacts the N-lobe of an acceptor kinase, causing allosteric activation of the
latter (yellow). MIG6 binds to the C-lobe (via AH1) and active site (via AH2) of the activated kinase domain. This results in immediate catalytic blockade of EGFR. Bottom: the
MIG6 EBR may also bind to ABL, with the AH1 and AH2 subdomains involved in contact with the C-lobe and active site of the ABL kinase, respectively. This results in catalytic
activation of ABL. SRC family kinases act downstream to EGFR and phosphorylate Tyr 488 (red dot) in the C-lobe of the ABL kinase domain, which prevents MIG6 from
activating ABL. Hence, activation of ABL by MIG6 requires low to absent EGFR activation (visualized by ligand-free monomeric EGFR) coupled to loss of Y488
phosphorylation. Likely, the phosphorylation status of ABL Y488 senses the overall abundance of receptor signals (RTKs, GPCRs, integrins) that promote growth and are
capable of activating SRC, although this has not been formally addressed as yet. For the sake of clarity, the graphic representation of ABL and SRC is limited to their TK
domain; inactive and active kinase domains are depicted in gray and yellow, respectively, regardless of their identity
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senescent cells in order to implement a state of unrespon-
siveness to growth stimuli.19
It is apparent from the above discussion that MIG6 may
operate in the maintenance of cell and tissue homeostasis not
only through growth inhibition, but also via the induction of cell
senescence and apoptosis. Thus, going back to our initial
questions, it is possible that, besides TEB filling, other
hyperplastic phenotypes observed in Errfi1 null mice are
caused, at least in part, by mitigated apoptosis. Escape from
senescence could instead contribute to the malignant
transformation of adenomas that develop in Errfi1 null
mice.8,12 Addressing these issues will require an expansion
of studies focused on tissue-specific ablation of Errfi1.
Genetic studies in the mouse will be extremely valuable also
for fostering our understanding of the pathogenic significance
and biologic liabilities attached to reduced MIG6 expression in
human tumors.8 We have also discussed evidence that
mouse phenotypes caused by Mig6 loss may not be caused
by excess ErbB function. ABL is a bona fide pro-apoptotic
MIG6 target and, plausibly, there could be more just awaiting
to be discovered.
As MIG6 biology expands, we need to gain insights into the
regulation of context-dependent MIG6 functions. We already
have some hints. For instance, ERRFI1 transcription in
response to growth stimuli and cellular stress is induced by
distinct signaling pathways that, in turn, drive occupancy of
the ERRFI1 promoter by different transcription factors.1,16,20
Interestingly, ERRFI1 expression appears to be much higher
in senescent rather than growing human fibroblasts.16
Plausibly, the high-level ERRFI1 transcription driven by
FOXOs could reflect the need for tout court cytostatic ErbB
repression in senescent and, more in general, stressed cells,
whereas lower levels of ERRFI1 expression in growing cells
would provide for fine tuning of the ErbB signal output. As
discussed above, growth signals funneled via SRC prevent
MIG6 from activating pro-apoptotic signals;9 stress signals
could likewise modulate MIG6 function by impacting on its
subcellular localization and/or interaction with effector/target
proteins involved in cell death regulation. Ultimately, in
stressed cells, regulatory inputs must dictate to MIG6 the
right course of action, namely imposition of a transient
proliferation blockade to allow recovery from damage as
opposed to promotion of either apoptosis or premature
senescence, should damage remain unresolved.
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